Related references
Note: Only part of the references are listed.Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma
Myron S. Czuczman et al.
ANNALS OF HEMATOLOGY (2015)
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
Tatyana Feldman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma - a phase II trial
Michelle Furtado et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Phosphoinositide 3-kinase inhibitors in lymphoma
Emily Curran et al.
CURRENT OPINION IN ONCOLOGY (2014)
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma
Matthew J. Matasar et al.
BLOOD (2013)
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma
Bertrand Coiffier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas
Amin Aalipour et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells
Susanne Hoerl et al.
HAEMATOLOGICA (2013)
Complete Remission After Treatment With Single-Agent Ofatumumab in a Patient With High-Risk Leukemic Mantle-Cell Lymphoma
Friederike Hunstig et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy
Luca Bologna et al.
JOURNAL OF IMMUNOLOGY (2013)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel et al.
LANCET (2013)
Transformed large B-cell lymphoma in rituximab-allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumab
Michael A. Linden et al.
LEUKEMIA & LYMPHOMA (2013)
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
Christian Klein et al.
MABS (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology
Jonathan Feld et al.
ONCOTARGET (2013)
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
Myron S. Czuczman et al.
BLOOD (2012)
Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma
Matthew J. Barth et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma
Myron S. Czuczman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Novel CD20 monoclonal antibodies for lymphoma therapy
Shundong Cang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Novel antibodies against follicular non-Hodgkin's lymphoma
Tom van Meerten et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2011)
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles et al.
LANCET (2011)
US Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab
Steven J. Lemery et al.
CLINICAL CANCER RESEARCH (2010)
Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies
Bruce D. Cheson
JOURNAL OF CLINICAL ONCOLOGY (2010)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The European Medicines Agency Review of Ofatumumab (Arzerra®) for the Treatment of Chronic Lymphocytic Leukemia in Patients Refractory to Fludarabine and Alemtuzumab: Summary of the Scientific Assessment of the European Medicines Agency Committee for Medicinal Products for Human Use
Iordanis Gravanis et al.
ONCOLOGIST (2010)
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
Anton Hagenbeek et al.
BLOOD (2008)
Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity
Bohua Li et al.
CANCER RESEARCH (2008)
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
Bertrand Coiffier et al.
BLOOD (2008)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
JL Teeling et al.
BLOOD (2004)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
